AMARILLO, Texas--(BUSINESS WIRE)--Amarillo Biosciences, Inc. (ABI) (OTCBB:AMAR) today announced the following developments: In Turkey, enrollment is 86% complete in a Phase 2 study of Behçet’s disease. In the United States, four new clinical sites have been opened to enroll patients in a Phase 2 clinical trial of oral warts. In Texas, enrollment will begin in October 2007 to test oral interferon as a treatment of chronic cough in COPD (chronic obstructive pulmonary disease) patients. In Australia, a human influenza study is planned in 2008. In Taiwan and China, ABI’s Taiwanese partners are expected to conduct a clinical trial in chronic active hepatitis C patients. These developments will help pave the way for the realization of the company’s ultimate goal: FDA approval for its low-dose oral interferon.
